Leveraging Non-Invasive Approaches in NAFLD and NASH Diagnosis and Clinical Research
June 27, 2017
Nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) is anticipated to become the next major health epidemic. NAFLD is a chronic disease ranging from fatty liver to NASH to advanced end stage liver failure. Currently, liver biopsy is the gold standard for clinical diagnosis of NASH and monitoring treatment response, but has several disadvantages. Therefore, alternative approaches for NASH diagnosis and assessment of therapeutic response are needed. Soluble biomarkers can be utilized to provide robust results in a cost-effective and non-invasive manner for diagnosing and tracking therapeutic outcomes, with the opportunity to assess treatment response earlier in clinical research.
In this webinar, Dr. Sabina Paglialunga of Celerion addresses the merits and limitations of non-invasive modalities such as ultrasound, magnetic resonance and elastography. Panels of soluble biomarkers that can distinguish between advanced fibrosis, NASH and fatty liver are also discussed.